Skip to Main Content

The Supreme Court ruled unanimously Thursday that anti-abortion doctors did not have standing to challenge the Food and Drug Administration’s regulation of the abortion pill mifepristone.

The decision in FDA v. Alliance for Hippocratic Medicine reverses an appeals court order to require in-person prescribing of mifepristone, which had been available though telehealth and mail orders since 2021. 


It’s a victory for the Biden administration’s efforts to protect access to reproductive health care in the wake of the court’s decision to overturn Roe v. Wade. It also affirms the FDA’s authority to regulate medicines, avoiding an outcome that the biopharmaceutical industry had warned could destabilize the drug approval process.

STAT+ Exclusive Story


This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in



Totals $468 per year

$39/month Get Started

Totals $468 per year



for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month



Save 15%

$399/year Get Started

Save 15%

11+ Users


Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users


Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.


STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.